Soliton, Inc.: insider trades · United States · SEC (Form 4)

About Soliton, Inc.

Soliton, Inc. (ticker: SOLY) was a United States medical device company that traded on the NASDAQ market. Founded in 2012 and incorporated in Delaware, the company developed a proprietary technology platform licensed from The University of Texas on behalf of the MD Anderson Cancer Center. Its core business sat within medical aesthetics and non-invasive skin-treatment technologies, with a particular emphasis on acoustic shockwave-based applications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000015/soly-20201231.htm?utm_source=openai)) Operationally, Soliton centered its development efforts on the RAP, or Rapid Acoustic Pulse, device. The company described RAP as a tool intended to help enable more efficient multi-pass laser treatments in a single office visit, and its public disclosures highlighted its use in aesthetic indications such as cellulite and fibrotic scars. In other words, Soliton was primarily a product-development medtech company: its value proposition depended on a differentiated device, intellectual property protection, and eventual regulatory clearance and commercialization. ([globenewswire.com](https://www.globenewswire.com/news-release/2018/11/29/1658848/0/en/Soliton-Inc-Developer-of-Patented-Shockwave-Technology-Prices-and-Launches-its-Nasdaq-Initial-Public-Offering.html?utm_source=openai)) From a competitive standpoint, Soliton operated in a crowded aesthetic-medical-device market populated by larger, better-capitalized players with broader product portfolios and established distribution footprints. Soliton’s strategy was to compete through technical differentiation rather than scale. For investors, that meant a classic small-cap medical technology risk profile: high dependence on clinical adoption, regulatory milestones, and access to funding, with execution risk remaining elevated until commercialization is proven. Its SEC filings explicitly noted the possibility that additional capital may be required to continue executing the business plan. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000015/soly-20201231.htm?utm_source=openai)) The company’s historical headquarters were in Houston, Texas, and its communications reflected a development-stage organization focused on advancing clinical programs, protecting brand and product assets, and moving toward broader market acceptance. The business was best understood as a niche medtech story rather than a diversified healthcare platform. For French-speaking investors, the important takeaway is that SOLY was a U.S.-listed innovation company in the health and medical-device space, not a mature pharmaceutical or hospital-services group. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000015/soly-20201231.htm?utm_source=openai)) Recent public records show insider transactions filed on SEC Form 4, confirming ongoing reporting activity by executives and directors during the period when the stock was still listed. The broader public record also indicates that Soliton later ceased to trade as an independent listed issuer under the SOLY symbol, which is essential context when interpreting any legacy references in datasets, filings, or insider-transaction feeds. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1548187/000154818721000081/0001548187-21-000081-index.htm?utm_source=openai))